

CURRICULUM VITAE

PERSONAL INFO

Name	Buonaguro Luigi
Birthday	16/08/1964
Degree	Medical Doctor
Institution	Istituto Nazionale per la Cura dei Tumori "Fond. Pascale"
Position	Head of the Immunoregulation Unit
Telephone	0815903273
Fax	0815451276
E-mail	l.buonaguro@istitutotumori.na.it

DEGREE AND PROFESSIONAL EXPERIENCES
--

DEGREE	1988	Medical Doctor <i>cum laude</i> – School of Medicine and Surgery, "Federico II" Univ., NAPOLI
CERTIFICATE	1992	Microbiology and Virology Certificate – School of Medicine and Surgery, "Federico II" Univ., NAPOLI
Working experiences	2017 – to date 2009 – 2017 2005 ad oggi 1998 – 2009 1993 – 1998 1996 1992 – 1993 1991 – 1992 1990	Head, Cancer Immunoregulatory Unit , Natl. Cancer Inst. "Pascale", Naples, ITALY Lab Head, Immunotherapy , Mol.Biol.&Viral Oncol., Natl. Cancer Inst. "Pascale", Naples, ITALY Adj. Ass. Professor , Dept of Medicine, Univ. of Maryland, School of Medicine, Baltimore MD, USA. Associate Member, Viral Oncol. , Natl. Cancer Institute "Pascale", Naples, ITALY Assistant Member, Viral Oncol. , Natl. Cancer Institute "Pascale", Naples, ITALY Short-term fellowship , Inst. Microbiol. Univ. di Regensburg – Germany. Fellow, Viral Oncol. , Natl. Cancer Institute "Pascale", Naples, ITALY Fogarty Fellow Lab. Of Tumor Cell Biology, Natl. Cancer Inst., Natl. Institutes of Health, Bethesda MD, USA (Prof. R.C. Gallo). Fellow A.I.R.C. (Italian Associatione for Cancer Research) Lab. Of Tumor Cell Biology, Natl. Cancer Inst., Natl. Institutes of Health, Bethesda MD, USA (Prof. R.C. Gallo).
Funding from 2011	2018 – 2020 2017 – 2019 2013 – 2018 2011-2013 2011-2012 2012-2013 2008-2011	Luigi Buonaguro (Co-P.I.) "Oncoterapia – Campania" – Project POR Campania € 15.247.500,00 Luigi Buonaguro (P.I.) "Mutated neo-antigens in hepatocellular carcinoma – HEPAMUT" – TRANSCAN European Union Commission € 1.100.000,00 Luigi Buonaguro (P.I.) "Cancer Vaccine development for Hepatocellular Carcinoma – HEPAVAC" (Grant Nr. 602893) – FP7 Grant European Union Commission € 5.996.110,00 Luigi Buonaguro (P.I.) "Development and evaluation of preventive and therapeutic immunological strategies (cancer vaccines) for hepatocellular carcinoma – Intramural funding € 120.000,00 Luigi Buonaguro (P.I.) "Systems biology for predictive biomarkers of responsiveness to cancer immunotherapy" - Takeda/Millennium (Grant Number X23002), € 85.000,00 Luigi Buonaguro (P.I.) "Contributions of anti-V2 antibodies in protection against HIV" – Sub-contract 12-01805 New York University , prime award 1 R01 AI102740-01 NIH/NIAID, USD 85.000,00 Luigi Buonaguro (Co-Investigator, P.I. F.M. Buonaguro) NIH-SVEU: Non-Human primates pre-clinical efficacy evaluation of VLPs-based HIV vaccine developed in the UO of Viral Oncology at

	the INT-Naples – National Institutes of Health, Bethesda MD, USA 2007-2012 Luigi Buonaguro (P.I. Unit INT) "New HIV Vaccines induce broadly-reactive neutralising antibodies." FP7 Grant European Union Commission. €7.534.742,00;
European Projects	2008 - 2012 (P.I. Unità e WORK PACKAGE LEADER) New HIV Vaccines induce broadly-reactive neutralising antibodies – NGIN (Nr. 201433). FP7 EU Grant. Budget totale €7.534.742,00; Budget Unità € 269.167,00 2013 – (COORDINATOR) "Cancer Vaccine development for Hepatocellular Carcinoma – HEPAVAC" (Grant Nr. 602893) – FP7 EU Grant della Commissione Europea € 5.996.110,00. 2017 – (COORDINATOR) "Mutated neo-antigens in hepatocellular carcinoma – HEPAMUT" – TRANSCAN Grant European Union Commission € 1.100.000,00
Experiences as expert in activities related to the EU (revision panel and/or Invited expert; advisory board);	2012 Evaluator EDCTP (European & Developing Countries Clinical Trials Partnership) call CT.2006.33111.001 2015 Evaluator European project ERACoSysMed - ERA-Net on Systems Medicine Horizon 2020 2014 – Expert Scientific Directorate for Italian Research Institutes
Other scientific/editorial activities	<ul style="list-style-type: none"> • Visiting Scientist at Institute of Human Virology, Univ. of Maryland, Baltimore, MD –USA (Dir. Prof. R.C. Gallo), Nov 2004 – March 2005; Aug - Sept 2005; Nov 2006. • Visiting Scientist Institute of Hygiene, Regensburg, Germany (Dir. Prof. H. Wolf), Dec 1996. <p>Reviewer and/or Editor</p> <ul style="list-style-type: none"> • Section Editor "<i>Immunovirology</i>" <i>Journal of Translational Medicine</i>; • Co-Editor in Chief <i>The Open AIDS Journal</i> • Editorial Board Member <i>European Journal of Inflammation</i>; • Editorial Board Member <i>Clinical Vaccine Immunology</i>; • Editorial Board Member <i>Immunotherapy</i>; • Editorial Board Member <i>Infectious Agents Cancer Journal</i>; • Editorial Board Member <i>Current HIV Research Journal</i>; • Ad Hoc Reviewer for <i>AIDS, JAIDS, J Virol, J Clinical Microbiol, Clinical Vaccine Immunol; J Immunol; PloSOne</i> • Reviewer for the National Medical Research Council of Singapore. • F1000 Medicine Faculty Member, Infectious Diseases Section. <p>Scientific Societies</p> <ul style="list-style-type: none"> • Member Italian Virology Society (SIV). • Member Italian Medical Virology Society (SIVIM). • Member American Society for Microbiology (ASM). • Member Association for Cancer Immunotherapy (CIMT) • Member American Association for Cancer Research (AACR) • Member Cancer Research Institute (CRI) <p>Teaching activities</p> <p>2014 National Board Full Professor Microbiology and Patology. 2003 - 2014 Microbiology and Virology courses, Biomedical Lab Technician, School of Medicine and Surgery, "Federico II" Univ., NAPOLI. 2001 - 2003 General Microbiology, Nursing School, School of Medicine and Surgery, Second Univ., NAPOLI.</p>
PATENTING	1. Buonaguro FM et al., " <i>Method for biomolecular detection of human liver diseases</i> " (PCT/EP2009/062716, WO 2011/038763 A1 del 07.04.2011); Indian National stage 3671/CHENP/2012 Ott 2012 2. Buonaguro FM et al., " <i>VLPs presenting trimeric and conformational molecules, including HIV-1 envelopes, and method for mucosal and sublingual immunization against HIV-1</i> " (PCT/EP2008/063912 - WO/2010/043259), Indian National stage 3170/CHENP/2011 Aug 31 st 2012
PUBLICATIONS	Dr. Luigi Buonaguro has published, as Author or co-Author, 154 papers . Total I.F. >500; H-index is 39 (Scopus). Guest Editor di un Topic Issues on: 1) " <i>Novel Vaccines and Adjuvants</i> " (<i>Current HIV Research Journal</i> , Vol. 8, 2010); 2) " <i>Differential use of CCR5 versus CXCR4 by HIV-1. Pathogenic, Translational and Clinical Open Questions</i> " (<i>J. of Translational Medicine</i> , 9(Suppl. 1), 2011); 3) " <i>Virus-Like Particles</i> " (<i>Exp Rev Vaccines</i> , Vol. 12(2), 2013); 4) " <i>New developments in Cancer Vaccines</i> " (<i>Exp Rev Vaccines</i> , Vol. 12(10), 2013).

Biobibliography Dr. Luigi Buonaguro

- 1: Petrizzo A, Tagliamonte M, Mauriello A, Costa V, Aprile M, Esposito R, Caporale A, Luciano A, Arra C, Tornesello ML, Buonaguro FM, **Buonaguro L**. Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. *J Transl Med*. 2018 Oct 19;16(1):286. doi: 10.1186/s12967-018-1662-9. PubMed PMID: 30340600.
- 2: Tagliamonte M, Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, **Buonaguro L**. Potentiating cancer vaccine efficacy in liver cancer. *Oncoimmunology*. 2018 Jul 23;7(10):e1488564. doi: 10.1080/2162402X.2018.1488564. eCollection 2018. PubMed PMID: 30288355; PubMed Central PMCID: PMC6169594.
- 3: Annunziata C, Stellato G, Greggi S, Sanna V, Curcio MP, Losito S, Botti G, **Buonaguro L**, Buonaguro FM, Tornesello ML. Prevalence of "unclassified" HPV genotypes among women with abnormal cytology. *Infect Agent Cancer*. 2018 Jul 24;13:26. doi: 10.1186/s13027-018-0199-0. eCollection 2018. PubMed PMID: 30061920; PubMed Central PMCID: PMC6056927.
- 4: Tornesello AL, **Buonaguro L**, Tornesello ML, Buonaguro FM. The role of sensing peptides in the cross-talk between microbiota and human cancer cells. *Mini Rev Med Chem*. 2018 Jul 12. doi: 10.2174/1389557518666180713112119. [Epub ahead of print] PubMed PMID: 30003859.
- 5: Ascierto PA, Brugarolas J, **Buonaguro L**, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). *J Immunother Cancer*. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review. PubMed PMID: 29996914; PubMed Central PMCID: PMC6042369.
- 6: Tornesello ML, Annunziata C, Tornesello AL, **Buonaguro L**, Buonaguro FM. Human Oncoviruses and p53 Tumor Suppressor Pathway Deregulation at the Origin of Human Cancers. *Cancers (Basel)*. 2018 Jun 22;10(7). pii: E213. doi: 10.3390/cancers10070213. Review. PubMed PMID: 29932446; PubMed Central PMCID: PMC6071257.
- 7: Annunziata C, Pezzuto F, Greggi S, Ionna F, Losito S, Botti G, **Buonaguro L**, Buonaguro FM, Tornesello ML. Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma. *Int J Cancer*. 2018 Sep 1;143(5):1153-1161. doi: 10.1002/ijc.31412. Epub 2018 Apr 17. PubMed PMID: 29603728.
- 8: Petrizzo A, Mauriello A, Tornesello ML, Buonaguro FM, Tagliamonte M, **Buonaguro L**. Cellular prognostic markers in hepatitis-related hepatocellular carcinoma. *Infect Agent Cancer*. 2018 Mar 27;13:10. doi: 10.1186/s13027-018-0183-8. eCollection 2018. Review. PubMed PMID: 29599818; PubMed Central PMCID: PMC5870199.
- 9: Pezzuto F, **Buonaguro L**, Buonaguro FM, Tornesello ML. The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma. *Int J Mol Sci*. 2018 Mar 28;19(4). pii: E1007. doi: 10.3390/ijms19041007. Review. PubMed PMID: 29597259; PubMed Central PMCID: PMC5979406.
- 10: Starita N, **Buonaguro L**, Buonaguro FM, Tornesello ML. Telomerase promoter mutations in human immunodeficiency virus-related conjunctiva neoplasia. *J Transl Med*. 2018 Mar 21;16(1):77. doi: 10.1186/s12967-018-1456-0. PubMed PMID: 29562930; PubMed Central PMCID: PMC5861639.
- 11: Petrizzo A, Mauriello A, Luciano A, Rea D, Barbieri A, Arra C, Maiolino P, Tornesello M, Gigantino V, Botti G, Ciliberto G, Buonaguro FM, Tagliamonte M, **Buonaguro L**. Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting. *Oncotarget*. 2017 Dec 8;9(3):3576-3589. doi: 10.18632/oncotarget.23181. eCollection 2018 Jan 9. PubMed PMID: 29423067; PubMed Central PMCID: PMC5790484.
- 12: **Buonaguro L**; HEPAVAC Consortium. Corrigendum to "New vaccination strategies in liver cancer" [Cytokine Growth Factor Rev. 36 (2017) 125-129]. *Cytokine Growth Factor Rev*. 2017 Sep 12. pii: S1359-6101(17)30149-1. doi: 10.1016/j.cytogfr.2017.09.001. [Epub ahead of print] PubMed PMID: 28918939.

- 13: Tornesello AL, **Buonaguro L**, Tornesello ML, Buonaguro FM. New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology. *Molecules*. 2017 Aug 2;22(8). pii: E1282. doi: 10.3390/molecules22081282. Review. PubMed PMID: 28767081.
- 14: **Buonaguro L**; HEPAVAC Consortium. New vaccination strategies in liver cancer. *Cytokine Growth Factor Rev*. 2017 Aug;36:125-129. doi: 10.1016/j.cytogfr.2017.06.010. Epub 2017 Jun 23. Erratum in: *Cytokine Growth Factor Rev*. 2017 Sep 12;:. PubMed PMID: 28688773.
- 15: Starita N, Di Monta G, Cerasuolo A, Marone U, Anniciello AM, Botti G, **Buonaguro L**, Buonaguro FM, Tornesello ML. Effect of electrochemotherapy on human herpesvirus 8 kinetics in classic Kaposi sarcoma. *Infect Agent Cancer*. 2017 Jun 19;12:35. doi: 10.1186/s13027-017-0147-4. eCollection 2017. PubMed PMID: 28649271; PubMed Central PMCID: PMC5477158.
- 16: Circelli L, Tornesello M, Buonaguro FM, **Buonaguro L**. Use of adjuvants for immunotherapy. *Hum Vaccin Immunother*. 2017 Aug 3;13(8):1774-1777. doi: 10.1080/21645515.2017.1321725. Epub 2017 Jun 12. PubMed PMID: 28604160; PubMed Central PMCID: PMC5557248.
- 17: Pezzuto F, **Buonaguro L**, Buonaguro FM, Tornesello ML. Frequency and geographic distribution of TERT promoter mutations in primary hepatocellular carcinoma. *Infect Agent Cancer*. 2017 May 19;12:27. doi: 10.1186/s13027-017-0138-5. eCollection 2017. Review. PubMed PMID: 28529542; PubMed Central PMCID: PMC5437489.
- 18: Cerasuolo A, Annunziata C, Tortora M, Starita N, Stellato G, Greggi S, Maglione MG, Ionna F, Losito S, Botti G, **Buonaguro L**, Buonaguro FM, Tornesello ML. Comparative analysis of HPV16 gene expression profiles in cervical and in oropharyngeal squamous cell carcinoma. *Oncotarget*. 2017 May 23;8(21):34070-34081. doi: 10.18632/oncotarget.15977. PubMed PMID: 28423662; PubMed Central PMCID: PMC5470952.
- 19: Petrizzo A, **Buonaguro L**. Application of the Immunoscore as prognostic tool for hepatocellular carcinoma. *J Immunother Cancer*. 2016 Nov 15;4:71. eCollection 2016. PubMed PMID: 27879973; PubMed Central PMCID: PMC5109780.
- 20: Circelli L, Petrizzo A, Tagliamonte M, Heidenreich R, Tornesello ML, Buonaguro FM, **Buonaguro L**. Immunological effects of a novel RNA-based adjuvant in liver cancer patients. *Cancer Immunol Immunother*. 2017 Jan;66(1):103-112. doi: 10.1007/s00262-016-1923-5. Epub 2016 Nov 10. PubMed PMID: 27832318.
- 21: Petrizzo A, Caruso FP, Tagliamonte M, Tornesello ML, Ceccarelli M, Costa V, Aprile M, Esposito R, Ciliberto G, Buonaguro FM, **Buonaguro L**. Identification and Validation of HCC-specific Gene Transcriptional Signature for Tumor Antigen Discovery. *Sci Rep*. 2016 Jul 8;6:29258. doi: 10.1038/srep29258. PubMed PMID: 27387388; PubMed Central PMCID: PMC4937235.
- 22: Gargiulo P, Della Pepa C, Berardi S, Califano D, Scala S, **Buonaguro L**, Ciliberto G, Brauchli P, Pignata S. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy? *Cancer Treat Rev*. 2016 Jul;48:61-8. doi: 10.1016/j.ctrv.2016.06.008. Epub 2016 Jun 18. Review. PubMed PMID: 27362548.
- 23: Pezzuto F, Izzo F, **Buonaguro L**, Annunziata C, Tatangelo F, Botti G, Buonaguro FM, Tornesello ML. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma. *Oncotarget*. 2016 Aug 23;7(34):54253-54262. doi: 10.18632/oncotarget.9801. PubMed PMID: 27276713; PubMed Central PMCID: PMC5342339.
- 24: Tortora M, Annunziata C, Liguori G, Losito S, Botti G, Greggi S, **Buonaguro L**, Buonaguro FM, Tornesello ML. Detection of human papillomavirus DNA in peri-tumor tissues and pelvic lymph nodes as potential molecular marker of micrometastasis in cervical cancer. *Infect Agent Cancer*. 2016 May 11;11:22. doi: 10.1186/s13027-016-0068-7. eCollection 2016. PubMed PMID: 27175213; PubMed Central PMCID: PMC4863320.
- 25: Buonaguro FM, **Buonaguro L**. Cancer vaccines for hepatocellular carcinoma: future directions. *Immunotherapy*. 2016;8(4):391-3. doi: 10.2217/imt-2015-0018. PubMed PMID: 26973120.
- 26: Tornesello ML, **Buonaguro L**, Izzo F, Buonaguro FM. Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. *Oncotarget*. 2016 May 3;7(18):25087-102. doi: 10.18632/oncotarget.7837. Review. PubMed PMID: 26943571; PubMed Central PMCID: PMC5041890.

- 27: Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Rea D, Barbieri A, Arra C, Maiolino P, Tornesello M, Ciliberto G, Buonaguro FM, **Buonaguro L**. A novel multi-drug metronomic chemotherapy significantly delays tumor growth in mice. *J Transl Med*. 2016 Feb 24;14:58. doi: 10.1186/s12967-016-0812-1. PubMed PMID: 26911136; PubMed Central PMCID: PMC4766679.
- 28: Tagliamonte M, Petrizzo A, Tornesello ML, Ciliberto G, Buonaguro FM, **Buonaguro L**. Combinatorial immunotherapy strategies for hepatocellular carcinoma. *Curr Opin Immunol*. 2016 Apr;39:103-13. doi: 10.1016/j.coi.2016.01.005. Epub 2016 Feb 4. Review. PubMed PMID: 26851637.
- 29: Starita N, Annunziata C, Waddell KM, **Buonaguro L**, Buonaguro FM, Tornesello ML. Identification of Human Herpesvirus 8 Sequences in Conjunctiva Intraepithelial Neoplasia and Squamous Cell Carcinoma of Ugandan Patients. *Biomed Res Int*. 2015;2015:801353. doi: 10.1155/2015/801353. Epub 2015 Oct 5. Review. PubMed PMID: 26509162; PubMed Central PMCID: PMC4609772.
- 30: Petrizzo A, Conte C, Tagliamonte M, Napolitano M, Bifulco K, Carriero V, De Stradis A, Tornesello ML, Buonaguro FM, Quaglia F, **Buonaguro L**. Functional characterization of biodegradable nanoparticles as antigen delivery system. *J Exp Clin Cancer Res*. 2015 Oct 6;34:114. doi: 10.1186/s13046-015-0231-9. PubMed PMID: 26444005; PubMed Central PMCID: PMC4596393.
- 31: Circelli L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM, **Buonaguro L**. Systems Biology Approach for Cancer Vaccine Development and Evaluation. *Vaccines (Basel)*. 2015 Jul 14;3(3):544-55. doi: 10.3390/vaccines3030544. Review. PubMed PMID: 26350594; PubMed Central PMCID: PMC4586466.
- 32: **Buonaguro L**; HEPAVAC Consortium. Developments in cancer vaccines for hepatocellular carcinoma. *Cancer Immunol Immunother*. 2016 Jan;65(1):93-9. doi: 10.1007/s00262-015-1728-y. Epub 2015 Jun 21. Review. PubMed PMID: 26093657.
- 33: Tornesello ML, **Buonaguro L**, Buonaguro FM. An overview of new biomolecular pathways in pathogen-related cancers. *Future Oncol*. 2015;11(11):1625-39. doi: 10.2217/fon.15.87. Review. PubMed PMID: 26043216.
- 34: **Buonaguro L**, Tagliamonte M, Petrizzo A, Damiano E, Tornesello ML, Buonaguro FM. Cellular prognostic markers in hepatocellular carcinoma. *Future Oncol*. 2015;11(11):1591-8. doi: 10.2217/fon.15.39. Review. PubMed PMID: 26043213.
- 35: Buonaguro FM, Tornesello ML, **Buonaguro L**. Foreword. *Cancer biomarkers. Future Oncol*. 2015;11(11):1585-6. doi: 10.2217/fon.15.74. PubMed PMID: 26043211.
- 36: Pezzuto F, **Buonaguro L**, Caponigro F, Ionna F, Starita N, Annunziata C, Buonaguro FM, Tornesello ML. Update on Head and Neck Cancer: Current Knowledge on Epidemiology, Risk Factors, Molecular Features and Novel Therapies. *Oncology*. 2015;89(3):125-36. doi: 10.1159/000381717. Epub 2015 May 8. Review. PubMed PMID: 25967534.
- 37: Maio M, Bertocci E, Pilla L, Fazio C, Chiarucci C, Cutaia O, Fonsatti E, Maccalli C, Parmiani G; NIBIT. "Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014. *Cancer Immunol Immunother*. 2016 Jan;65(1):119-26. doi: 10.1007/s00262-015-1699-z. Epub 2015 May 6. PubMed PMID: 25944004.
- 38: Tagliamonte M, Petrizzo A, Napolitano M, Luciano A, Arra C, Maiolino P, Izzo F, Tornesello ML, Aurisicchio L, Ciliberto G, Buonaguro FM, **Buonaguro L**. Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model. *Cancer Immunol Immunother*. 2015 Oct;64(10):1305-14. doi: 10.1007/s00262-015-1698-0. Epub 2015 May 6. PubMed PMID: 25944003.
- 39: Buonaguro FM, Tornesello ML, **Buonaguro L**. The XIX century smallpox prevention in Naples and the risk of transmission of human blood-related pathogens. *J Transl Med*. 2015 Jan 27;13:33. doi: 10.1186/s12967-015-0400-9. PubMed PMID: 25622683; PubMed Central PMCID: PMC4328853.
- 40: **Buonaguro L**. TIE2-expressing monocytes: a possible cellular diagnostic and prognostic biomarker for hepatocellular carcinoma. *Hepatobiliary Surg Nutr*. 2014 Dec;3(6):419-20. doi: 10.3978/j.issn.2304-3881.2014.07.02. PubMed PMID: 25568866; PubMed Central PMCID: PMC4273117.
- 41: Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, **Buonaguro L**. Antigen-specific vaccines for cancer treatment. *Hum Vaccin Immunother*. 2014;10(11):3332-46. doi:

- 10.4161/21645515.2014.973317. Review. PubMed PMID: 25483639; PubMed Central PMCID: PMC4514024.
- 42: Tornesello ML, Annunziata C, **Buonaguro L**, Losito S, Greggi S, Buonaguro FM. TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix. *J Transl Med.* 2014 Sep 16;12:255. doi: 10.1186/s12967-014-0255-5. PubMed PMID: 25220666; PubMed Central PMCID: PMC4174264.
- 43: Tornesello ML, Perri F, **Buonaguro L**, Ionna F, Buonaguro FM, Caponigro F. HPV-related oropharyngeal cancers: from pathogenesis to new therapeutic approaches. *Cancer Lett.* 2014 Sep 1;351(2):198-205. doi: 10.1016/j.canlet.2014.06.003. Epub 2014 Jun 24. Review. PubMed PMID: 24971935.
- 44: Shoja Z, Tagliamonte M, Jalilvand S, Mollaei-Kandelous Y, De Stradis A, Tornesello ML, Buonaguro FM, **Buonaguro L**. Formation of self-assembled triple-layered rotavirus-like particles (tIRLPs) by constitutive co-expression of VP2, VP6, and VP7 in stably transfected high-five insect cell lines. *J Med Virol.* 2015 Jan;87(1):102-11. doi: 10.1002/jmv.23973. Epub 2014 May 5. PubMed PMID: 24797918.
- 45: Petrizzo A, Tagliamonte M, Tornesello M, Buonaguro FM, **Buonaguro L**. Systems vaccinology for cancer vaccine development. *Expert Rev Vaccines.* 2014 Jun;13(6):711-9. doi: 10.1586/14760584.2014.913484. Epub 2014 Apr 28. Review. PubMed PMID: 24766452.
- 46: Tornesello ML, Giorgi Rossi P, **Buonaguro L**, Buonaguro FM; HPV Prevalence Italian Working Group. Human Papillomavirus Infection and Cervical Neoplasia among Migrant Women Living in Italy. *Front Oncol.* 2014 Feb 20;4:31. doi: 10.3389/fonc.2014.00031. eCollection 2014. PubMed PMID: 24600587; PubMed Central PMCID: PMC3929937.
- 47: Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM, **Buonaguro L**. Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach. *J Transl Med.* 2014 Jan 15;12:11. doi: 10.1186/1479-5876-12-11. PubMed PMID: 24428943; PubMed Central PMCID: PMC3903560.
- 48: Tornesello ML, **Buonaguro L**, Giorgi-Rossi P, Buonaguro FM. Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. *Biomed Res Int.* 2013;2013:519619. doi: 10.1155/2013/519619. Epub 2013 Dec 9. Review. PubMed PMID: 24383054; PubMed Central PMCID: PMC3872027.
- 49: Buonaguro FM, Tornesello ML, Izzo F, **Buonaguro L**. Oncolytic virus therapies. *Pharm Pat Anal.* 2012 Nov;1(5):621-7. doi: 10.4155/ppa.12.65. Review. PubMed PMID: 24236929.
- 50: Ungaro F, Conte C, Quaglia F, Tornesello ML, Buonaguro FM, **Buonaguro L**. VLPs and particle strategies for cancer vaccines. *Expert Rev Vaccines.* 2013 Oct;12(10):1173-93. doi: 10.1586/14760584.2013.836909. Review. PubMed PMID: 24124878.
- 51: **Buonaguro L**, Aurisicchio L, Buonaguro FM, Ciliberto G. New developments in cancer vaccines. *Expert Rev Vaccines.* 2013 Oct;12(10):1109-10. doi: 10.1586/17476348.2013.838013. PubMed PMID: 24124872.
- 52: Heyndrickx L, Stewart-Jones G, Jansson M, Schuitemaker H, Bowles E, **Buonaguro L**, Grevstad B, Vinner L, Vereecken K, Parker J, Ramaswamy M, Biswas P, Vanham G, Scarlatti G, Fomsgaard A; NGIN Consortium. Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model. *PLoS One.* 2013 Sep 2;8(9):e74552. doi: 10.1371/journal.pone.0074552. eCollection 2013. PubMed PMID: 24023951; PubMed Central PMCID: PMC3759472.
- 53: Visciano ML, Tagliamonte M, Stewart-Jones G, Heyndrickx L, Vanham G, Jansson M, Fomsgaard A, Grevstad B, Ramaswamy M, Buonaguro FM, Tornesello ML, Biswas P, Scarlatti G, **Buonaguro L**; NGIN Consortium. Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate. *J Transl Med.* 2013 Jul 8;11:165. doi: 10.1186/1479-5876-11-165. PubMed PMID: 23835244; PubMed Central PMCID: PMC3729709.
- 54: **Buonaguro L**, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM. Challenges in cancer vaccine development for hepatocellular carcinoma. *J Hepatol.* 2013 Oct;59(4):897-903. doi: 10.1016/j.jhep.2013.05.031. Epub 2013 May 25. Review. Erratum in: *J Hepatol.* 2014 Jan;60(1):237. PubMed PMID: 23714157.

- 55: Ponterio E, Petrizzo A, Di Bartolo I, Buonaguro FM, **Buonaguro L**, Ruggeri FM. Pattern of activation of human antigen presenting cells by genotype GII.4 norovirus virus-like particles. *J Transl Med*. 2013 May 24;11:127. doi: 10.1186/1479-5876-11-127. PubMed PMID: 23705987; PubMed Central PMCID: PMC3671189.
- 56: **Buonaguro L**, Tagliamonte M, Visciano ML. Chemokine receptor interactions with virus-like particles. *Methods Mol Biol*. 2013;1013:57-66. doi: 10.1007/978-1-62703-426-5_5. PubMed PMID: 23625493.
- 57: Tornesello ML, **Buonaguro L**, Tatangelo F, Botti G, Izzo F, Buonaguro FM. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. *Genomics*. 2013 Aug;102(2):74-83. doi: 10.1016/j.ygeno.2013.04.001. Epub 2013 Apr 11. Review. PubMed PMID: 23583669.
- 58: De Giorgi V, **Buonaguro L**, Worschech A, Tornesello ML, Izzo F, Marincola FM, Wang E, Buonaguro FM. Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis. *PLoS One*. 2013;8(2):e56153. doi: 10.1371/journal.pone.0056153. Epub 2013 Feb 18. PubMed PMID: 23441164; PubMed Central PMCID: PMC3575468.
- 59: **Buonaguro L**, Tagliamonte M, Visciano ML, Tornesello ML, Buonaguro FM. Developments in virus-like particle-based vaccines for HIV. *Expert Rev Vaccines*. 2013 Feb;12(2):119-27. doi: 10.1586/erv.12.152. Review. PubMed PMID: 23414404.
- 60: Buonaguro F, **Buonaguro L**. The application of virus-like particles to human diseases. *Expert Rev Vaccines*. 2013 Feb;12(2):99. doi: 10.1586/erv.12.154. PubMed PMID: 23414399.
- 61: Annunziata C, **Buonaguro L**, Losito S, Buonaguro FM, Tornesello ML. Somatic mutations of STK11 gene in human papillomavirus positive and negative penile cancer. *Infect Agent Cancer*. 2013 Jan 10;8(1):2. doi: 10.1186/1750-9378-8-2. PubMed PMID: 23305393; PubMed Central PMCID: PMC3584742.
- 62: Shoja Z, Tagliamonte M, Jalilvand S, Mokhtari-Azad T, Hamkar R, Shahmahmoodi S, Rezaei F, Tornesello M, Buonaguro FM, **Buonaguro L**, Nategh R. Development of a stable insect cell line constitutively expressing rotavirus VP2. *Virus Res*. 2013 Mar;172(1-2):66-74. doi: 10.1016/j.virusres.2012.12.015. Epub 2012 Dec 31. PubMed PMID: 23287060.
- 63: Tornesello ML, **Buonaguro L**, Buonaguro FM. Mutations of the TP53 gene in adenocarcinoma and squamous cell carcinoma of the cervix: a systematic review. *Gynecol Oncol*. 2013 Mar;128(3):442-8. doi: 10.1016/j.ygyno.2012.11.017. Epub 2012 Nov 17. Review. PubMed PMID: 23168175.
- 64: Shoja Z, Tagliamonte M, Jalilvand S, Ziaee AA, Mokhtari-Azad T, Hamkar R, Shahmahmoodi S, Rezaei F, Tornesello M, Buonaguro FM, Nategh R, **Buonaguro L**. Molecular characterization analysis of the outer protein layer (VP7) from human rotavirus A genotype G1 isolate identified in Iran: implications for vaccine development. *New Microbiol*. 2012 Oct;35(4):415-27. Epub 2012 Oct 1. PubMed PMID: 23109009.
- 65: Petrizzo A, Tornesello ML, Napolitano M, D'Alessio G, Salomone Megna A, Dolcetti R, De Re V, Wang E, Marincola FM, Buonaguro FM, **Buonaguro L**. Multiparametric analyses of human PBMCs loaded ex vivo with a candidate idio-type vaccine for HCV-related lymphoproliferative disorders. *PLoS One*. 2012;7(9):e44870. doi: 10.1371/journal.pone.0044870. Epub 2012 Sep 18. PubMed PMID: 23028651; PubMed Central PMCID: PMC3445594.
- 66: Tagliamonte M, Marasco D, Ruggiero A, De Stradis A, Tornesello ML, Totrov M, Buonaguro FM, **Buonaguro L**. HIV p24 as scaffold for presenting conformational HIV Env antigens. *PLoS One*. 2012;7(8):e43318. doi: 10.1371/journal.pone.0043318. Epub 2012 Aug 17. PubMed PMID: 22912852; PubMed Central PMCID: PMC3422313.
- 67: Petrizzo A, Tornesello M, Buonaguro FM, **Buonaguro L**. Immunogenomics approaches for vaccine evaluation. *J Immunotoxicol*. 2012 Jul-Sep;9(3):236-40. doi: 10.3109/1547691X.2012.707698. Review. PubMed PMID: 22894136.
- 68: Tornesello ML, **Buonaguro L**, Buonaguro FM. Advances in viral oncology research: summary of the 3rd International Meeting. *Expert Rev Vaccines*. 2012 Apr;11(4):411-4. doi: 10.1586/erv.12.14. PubMed PMID: 22551025.
- 69: **Buonaguro L**, Tagliamonte M, Visciano ML, Andersen H, Lewis M, Pal R, Tornesello ML, Schroeder U, Hinkula J, Wahren B, Buonaguro FM. Immunogenicity of HIV virus-like particles in rhesus macaques by

- intranasal administration. *Clin Vaccine Immunol.* 2012 Jun;19(6):970-3. doi: 10.1128/CVI.00068-12. Epub 2012 Mar 29. PubMed PMID: 22461530; PubMed Central PMCID: PMC3370444.
- 70: Annunziata C, **Buonaguro L**, Buonaguro FM, Tornesello ML. Characterization of the human papillomavirus (HPV) integration sites into genital cancers. *Pathol Oncol Res.* 2012 Oct;18(4):803-8. Epub 2012 Mar 27. PubMed PMID: 22451136.
- 71: **Buonaguro L**, Petrizzo A, Tornesello ML, Buonaguro FM. Innate immunity and hepatitis C virus infection: a microarray's view. *Infect Agent Cancer.* 2012 Mar 26;7(1):7. doi: 10.1186/1750-9378-7-7. PubMed PMID: 22448617; PubMed Central PMCID: PMC3511806.
- 72: Visciano ML, Tagliamonte M, Tornesello ML, Buonaguro FM, **Buonaguro L**. Effects of adjuvants on IgG subclasses elicited by virus-like particles. *J Transl Med.* 2012 Jan 5;10:4. doi: 10.1186/1479-5876-10-4. PubMed PMID: 22221900; PubMed Central PMCID: PMC3311067.
- 73: Tornesello ML, de Rosa N, Sarappa F, **Buonaguro L**, Piccoli R, Buonaguro FM. Assessment of Chlamydia trachomatis infection among Eastern European and West African women immigrants in South Italy. *Sex Transm Infect.* 2012 Feb;88(1):70-1. doi: 10.1136/sextrans-2011-050361. Epub 2011 Nov 30. PubMed PMID: 22130975.
- 74: **Buonaguro L**, Tagliamonte M, Tornesello ML, Buonaguro FM. Developments in virus-like particle-based vaccines for infectious diseases and cancer. *Expert Rev Vaccines.* 2011 Nov;10(11):1569-83. doi: 10.1586/erv.11.135. Review. PubMed PMID: 22043956.
- 75: Cools N, Petrizzo A, Smits E, Buonaguro FM, Tornesello ML, Berneman Z, **Buonaguro L**. Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons? *Immunotherapy.* 2011 Oct;3(10):1203-22. doi: 10.2217/imt.11.110. Review. PubMed PMID: 21995572.
- 76: Jalilvand S, Tornesello ML, Buonaguro FM, **Buonaguro L**, Naraghi ZS, Shoja Z, Ziaee AA, Hamkar R, Shahmahmoodi S, Nategh R, Mokhtari-Azad T. Molecular epidemiology of human herpesvirus 8 variants in Kaposi's sarcoma from Iranian patients. *Virus Res.* 2012 Feb;163(2):644-9. doi: 10.1016/j.virusres.2011.09.027. Epub 2011 Sep 22. PubMed PMID: 21963664.
- 77: **Buonaguro L**, Wang E, Tornesello ML, Buonaguro FM, Marincola FM. Systems biology applied to vaccine and immunotherapy development. *BMC Syst Biol.* 2011 Sep 20;5:146. doi: 10.1186/1752-0509-5-146. Review. PubMed PMID: 21933421; PubMed Central PMCID: PMC3191374.
- 78: Tornesello ML, Cassese R, De Rosa N, **Buonaguro L**, Masucci A, Vallefucio G, Palmieri S, Schiavone V, Piccoli R, Buonaguro FM. High prevalence of human papillomavirus infection in Eastern European and West African women immigrants in South Italy. *APMIS.* 2011 Oct;119(10):701-9. doi: 10.1111/j.1600-0463.2011.02784.x. Epub 2011 Jun 23. PubMed PMID: 21917007.
- 79: **Buonaguro L**, Tagliamonte M, Tornesello ML, Buonaguro FM. Can HIV p24 be a suitable scaffold for presenting Env antigens? *Clin Vaccine Immunol.* 2011 Nov;18(11):2003-4. doi: 10.1128/CVI.05326-11. Epub 2011 Sep 7. PubMed PMID: 21900531; PubMed Central PMCID: PMC3209041.
- 80: Di Vuolo V, **Buonaguro L**, Izzo F, Losito S, Botti G, Buonaguro FM, Tornesello ML. TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. *Infect Agent Cancer.* 2011 Aug 15;6:13. doi: 10.1186/1750-9378-6-13. PubMed PMID: 21843334; PubMed Central PMCID: PMC3170208.
- 81: Buonaguro FM, Tornesello ML, **Buonaguro L**. New adjuvants in evolving vaccine strategies. *Expert Opin Biol Ther.* 2011 Jul;11(7):827-32. doi: 10.1517/14712598.2011.587802. Epub 2011 May 24. PubMed PMID: 21609186.
- 82: Tagliamonte M, Visciano ML, Tornesello ML, De Stradis A, Buonaguro FM, **Buonaguro L**. HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line. *Vaccine.* 2011 Jul 12;29(31):4913-22. doi: 10.1016/j.vaccine.2011.05.004. Epub 2011 May 17. PubMed PMID: 21596085.
- 83: Visciano ML, Diomedea L, Tagliamonte M, Tornesello ML, Asti V, Bomsel M, Buonaguro FM, Lopalco L, **Buonaguro L**. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. *Vaccine.* 2011 Jul 12;29(31):4903-12. doi: 10.1016/j.vaccine.2011.05.005. Epub 2011 May 17. PubMed PMID: 21596074.

- 84: Tagliamonte M, Tornesello ML, Buonaguro FM, **Buonaguro L**. Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies. *J Transl Med*. 2011 Jan 27;9 Suppl 1:S1. doi: 10.1186/1479-5876-9-S1-S1. Review. PubMed PMID: 21284899; PubMed Central PMCID: PMC3105500.
- 85: Poli G, **Buonaguro L**. Introducing the issue on "differential use of CCR5 versus CXCR4 by HIV-1. Pathogenic, translational and clinical open questions". *J Transl Med*. 2011 Jan 27;9 Suppl 1:I1. doi: 10.1186/1479-5876-9-S1-I1. PubMed PMID: 21284898; PubMed Central PMCID: PMC3105499.
- 86: Hemelaar J, Gouws E, Ghys PD, Osmanov S; WHO-UNAIDS Network for HIV Isolation and Characterisation. Global trends in molecular epidemiology of HIV-1 during 2000-2007. *AIDS*. 2011 Mar 13;25(5):679-89. doi: 10.1097/QAD.0b013e328342ff93. PubMed PMID: 21297424; PubMed Central PMCID: PMC3755761.
- 87: De Rossi A, Zanchetta M, Vitone F, Antonelli G, Bagnarelli P, **Buonaguro L**, Capobianchi MR, Clementi M, Abbate I, Canducci F, Monachetti A, Riva E, Rozera G, Scagnolari C, Tagliamonte M, Re MC; SIVIM (Italian Society of Medical Virology) Group. Quantitative HIV-1 proviral DNA detection: a multicentre analysis. *New Microbiol*. 2010 Oct;33(4):293-302. PubMed PMID: 21213587.
- 88: Tornesello ML, Losito S, Benincasa G, Fulciniti F, Botti G, Greggi S, **Buonaguro L**, Buonaguro FM. Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. *Gynecol Oncol*. 2011 Apr;121(1):32-42. doi: 10.1016/j.ygyno.2010.12.005. Epub 2011 Jan 6. PubMed PMID: 21211829.
- 89: **Buonaguro L**, Pulendran B. Immunogenomics and systems biology of vaccines. *Immunol Rev*. 2011 Jan;239(1):197-208. doi: 10.1111/j.1600-065X.2010.00971.x. Review. PubMed PMID: 21198673; PubMed Central PMCID: PMC3253346.
- 90: **Buonaguro L**, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. *Clin Vaccine Immunol*. 2011 Jan;18(1):23-34. doi: 10.1128/CVI.00286-10. Epub 2010 Nov 3. Review. PubMed PMID: 21048000; PubMed Central PMCID: PMC3019775.
- 91: Tornesello ML, **Buonaguro L**, Cristillo M, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, Ruocco V, Viviano E, Romano N, Katongole-Mbidde E, Buonaguro FM. MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients. *Biomarkers*. 2011 Feb;16(1):42-50. doi: 10.3109/1354750X.2010.525664. Epub 2010 Oct 28. PubMed PMID: 20979563.
- 92: Tagliamonte M, Visciano ML, Tornesello ML, De Stradis A, Buonaguro FM, **Buonaguro L**. Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system. *Vaccine*. 2010 Sep 7;28(39):6417-24. doi: 10.1016/j.vaccine.2010.07.054. Epub 2010 Aug 2. PubMed PMID: 20678589.
- 93: Scotti N, **Buonaguro L**, Tornesello ML, Cardi T, Buonaguro FM. Plant-based anti-HIV-1 strategies: vaccine molecules and antiviral approaches. *Expert Rev Vaccines*. 2010 Aug;9(8):925-36. doi: 10.1586/erv.10.79. Review. PubMed PMID: 20673014.
- 94: Tornesello ML, Loquercio G, Tagliamonte M, Rossano F, **Buonaguro L**, Buonaguro FM. Human papillomavirus infection in urine samples from male renal transplant patients. *J Med Virol*. 2010 Jul;82(7):1179-85. doi: 10.1002/jmv.21784. PubMed PMID: 20513081.
- 95: **Buonaguro L**. Novel vaccines and adjuvants. *Curr HIV Res*. 2010 Jun;8(4):273. PubMed PMID: 20462398.
- 96: Ross AL, Bråve A, Scarlatti G, Manrique A, **Buonaguro L**. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. *Lancet Infect Dis*. 2010 May;10(5):305-16. doi: 10.1016/S1473-3099(10)70069-4. PubMed PMID: 20417413.
- 97: **Buonaguro L**, Tornesello ML, Buonaguro FM. Virus-like particles as particulate vaccines. *Curr HIV Res*. 2010 Jun;8(4):299-309. Review. PubMed PMID: 20353398.
- 98: **Buonaguro L**, Petrizzo A, Tornesello M, Napolitano M, Martorelli D, Castello G, Beneduce G, De Renzo A, Perrella O, Romagnoli L, Sousa V, De Re V, Dolcetti R, Buonaguro FM. Immune signatures in human PBMCs of idiotype vaccine for HCV-related lymphoproliferative disorders. *J Transl Med*. 2010 Feb 19;8:18. doi: 10.1186/1479-5876-8-18. PubMed PMID: 20170491; PubMed Central PMCID: PMC2839974.

- 99: Tornesello ML, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, Ruocco V, Katongole-Mbidde E, Loquercio G, **Buonaguro L**, Buonaguro FM. Human herpesvirus type 8 variants circulating in Europe, Africa and North America in classic, endemic and epidemic Kaposi's sarcoma lesions during pre-AIDS and AIDS era. *Virology*. 2010 Mar 15;398(2):280-9. doi: 10.1016/j.virol.2009.12.005. Epub 2010 Jan 15. PubMed PMID: 20079510.
- 100: Tornesello ML, Biryahwaho B, Downing R, Hatzakis A, Alessi E, Cusini M, Ruocco V, Katongole-Mbidde E, **Buonaguro L**, Buonaguro FM. TP53 codon 72 polymorphism in classic, endemic and epidemic Kaposi's sarcoma in African and Caucasian patients. *Oncology*. 2009;77(5):328-34. doi: 10.1159/000260905. Epub 2009 Nov 23. PubMed PMID: 19940524.
- 101: De Giorgi V, Monaco A, Worchech A, Tornesello M, Izzo F, **Buonaguro L**, Marincola FM, Wang E, Buonaguro FM. Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. *J Transl Med*. 2009 Oct 12;7:85. doi: 10.1186/1479-5876-7-85. PubMed PMID: 19821982; PubMed Central PMCID: PMC2768694.
- 102: Buonaguro FM, Tornesello ML, **Buonaguro L**. Virus-like particle vaccines and adjuvants: the HPV paradigm. *Expert Rev Vaccines*. 2009 Oct;8(10):1379-98. doi: 10.1586/erv.09.81. Review. PubMed PMID: 19803760.
- 103: Monaco A, Marincola FM, Sabatino M, Pos Z, Tornesello ML, Stroncek DF, Wang E, Lewis GK, Buonaguro FM, **Buonaguro L**. Molecular immune signatures of HIV-1 vaccines in human PBMCs. *FEBS Lett*. 2009 Sep 17;583(18):3004-8. doi: 10.1016/j.febslet.2009.07.060. Epub 2009 Aug 6. PubMed PMID: 19665024; PubMed Central PMCID: PMC3418664.
- 104: **Buonaguro L**, Tornesello ML, Jewis GK, Buonaguro FM. Short communication: limited induction of IL-10 in PBMCs from HIV-infected subjects treated with HIV-VLPs. *AIDS Res Hum Retroviruses*. 2009 Aug;25(8):819-22. doi: 10.1089/aid.2008.0304. PubMed PMID: 19630502; PubMed Central PMCID: PMC2858928.
- 105: Tornesello ML, Monaco R, Nappi O, **Buonaguro L**, Buonaguro FM. Detection of mucosal and cutaneous human papillomaviruses in oesophagitis, squamous cell carcinoma and adenocarcinoma of the oesophagus. *J Clin Virol*. 2009 May;45(1):28-33. doi: 10.1016/j.jcv.2009.02.004. PubMed PMID: 19307150.
- 106: Scotti N, Alagna F, Ferraiolo E, Formisano G, Sannino L, **Buonaguro L**, De Stradis A, Vitale A, Monti L, Grillo S, Buonaguro FM, Cardi T. High-level expression of the HIV-1 Pr55gag polyprotein in transgenic tobacco chloroplasts. *Planta*. 2009 Apr;229(5):1109-22. doi: 10.1007/s00425-009-0898-2. Epub 2009 Feb 21. PubMed PMID: 19234717.
- 107: Alter G, Ananworanich J, Pantophlet R, Rybicki EP, **Buonaguro L**. Report on the AIDS Vaccine 2008 Conference. *Hum Vaccin*. 2009 Mar;5(3):119-25. Epub 2009 Mar 8. PubMed PMID: 19202348.
- 108: Abbadessa G, Accolla R, Aiuti F, Albini A, Aldovini A, Alfano M, Antonelli G, Bartholomew C, Bentwich Z, Bertazzoni U, Berzofsky JA, Biberfeld P, Boeri E, **Buonaguro L**, Buonaguro FM, Bukrinsky M, Burny A, Caruso A, Cassol S, Chandra P, Ceccherini-Nelli L, Chieco-Bianchi L, Clerici M, Colombini-Hatch S, de Giuli Morghen C, de Maria A, de Rossi A, Dierich M, Della-Favera R, Dolei A, Douek D, Erfle V, Felber B, Fiorentini S, Franchini G, Gershoni JM, Gotch F, Green P, Greene WC, Hall W, Haseltine W, Jacobson S, Kallings LO, Kalyanaraman VS, Katinger H, Khalili K, Klein G, Klein E, Klotman M, Klotman P, Kotler M, Kurth R, Lafeuillade A, La Placa M, Lewis J, Lillo F, Lisziewicz J, Lomonico A, Lopalco L, Lori F, Lusso P, Macchi B, Malim M, Margolis L, Markham PD, McClure M, Miller N, Mingari MC, Moretta L, Noonan D, O'Brien S, Okamoto T, Pal R, Palese P, Panet A, Pantaleo G, Pavlakis G, Pistello M, Plotkin S, Poli G, Pomerantz R, Radaelli A, Robertguroff M, Roederer M, Sarngadharan MG, Schols D, Secchiero P, Shearer G, Siccardi A, Stevenson M, Svoboda J, Tartaglia J, Torelli G, Tornesello ML, Tschachler E, Vaccarezza M, Vallbracht A, van Lunzen J, Varnier O, Vicenzi E, von Melchner H, Witz I, Zagury D, Zagury JF, Zauli G, Zipeto D. *Unsung hero Robert C. Gallo*. *Science*. 2009 Jan 9;323(5911):206-7. doi: 10.1126/science.323.5911.206. PubMed PMID: 19131607.
- 109: **Buonaguro L**, Tornesello ML, Gallo RC, Marincola FM, Lewis GK, Buonaguro FM. Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles. *J Virol*. 2009 Jan;83(1):304-13. doi: 10.1128/JVI.01606-08. Epub 2008 Oct 22. PubMed PMID: 18945779; PubMed Central PMCID: PMC2612330.

- 110: **Buonaguro L**, Petrizzo A, Tagliamonte M, Vitone F, Re MC, Pilotti E, Casoli C, Sbreglia C, Perrella O, Tornesello ML, Buonaguro FM. Molecular and phylogenetic analysis of HIV-1 variants circulating in Italy. *Infect Agent Cancer*. 2008 Oct 10;3:13. doi: 10.1186/1750-9378-3-13. PubMed PMID: 18847472; PubMed Central PMCID: PMC2586622.
- 111: Tornesello ML, **Buonaguro L**, Izzo S, Lopez G, Vega X, Maldonado Reyes CF, Buonaguro FM. A pilot study on the distribution of human papillomavirus genotypes and HPV-16 variants in cervical neoplastic lesions from Ecuadorian women. *J Med Virol*. 2008 Nov;80(11):1959-65. doi: 10.1002/jmv.21317. PubMed PMID: 18814248.
- 112: Tornesello ML, Duraturo ML, Guida V, Losito S, Botti G, Pilotti S, Stefanon B, De Palo G, **Buonaguro L**, Buonaguro FM. Analysis of TP53 codon 72 polymorphism in HPV-positive and HPV-negative penile carcinoma. *Cancer Lett*. 2008 Sep 28;269(1):159-64. doi: 10.1016/j.canlet.2008.04.027. Epub 2008 May 29. PubMed PMID: 18513854.
- 113: Tornesello ML, Duraturo ML, Giorgi-Rossi P, Sansone M, Piccoli R, **Buonaguro L**, Buonaguro FM. Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women. *J Gen Virol*. 2008 Jun;89(Pt 6):1380-9. doi: 10.1099/vir.0.83553-0. PubMed PMID: 18474553.
- 114: **Buonaguro L**, Monaco A, Aricò E, Wang E, Tornesello ML, Lewis GK, Marincola FM, Buonaguro FM. Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. *BMC Bioinformatics*. 2008 Mar 26;9 Suppl 2:S5. doi: 10.1186/1471-2105-9-S2-S5. PubMed PMID: 18387207; PubMed Central PMCID: PMC2323668.
- 115: Tagliamonte M, Naderi HR, Tornesello ML, Farid R, Buonaguro FM, **Buonaguro L**. HIV type 1 subtype A epidemic in injecting drug user (IDU) communities in Iran. *AIDS Res Hum Retroviruses*. 2007 Dec;23(12):1569-74. Erratum in: *AIDS Res Hum Retroviruses*. 2008 Feb;24(2):345. PubMed PMID: 18160015.
- 116: Duraturo ML, Tornesello ML, **Buonaguro L**, Buonaguro FM. [Mucosotropic papillomavirus genotypes in the Italian population]. *Minerva Ginecol*. 2007 Oct;59(5):553-5. Italian. PubMed PMID: 17912182.
- 117: Tornesello ML, Duraturo ML, Losito S, Botti G, Pilotti S, Stefanon B, De Palo G, Gallo A, **Buonaguro L**, Buonaguro FM. Human papillomavirus genotypes and HPV16 variants in penile carcinoma. *Int J Cancer*. 2008 Jan 1;122(1):132-7. PubMed PMID: 17764110.
- 118: **Buonaguro L**, Tornesello ML, Buonaguro FM. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. *J Virol*. 2007 Oct;81(19):10209-19. Epub 2007 Jul 18. Review. PubMed PMID: 17634242; PubMed Central PMCID: PMC2045484.
- 119: **Buonaguro L**, Devito C, Tornesello ML, Schröder U, Wahren B, Hinkula J, Buonaguro FM. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. *Vaccine*. 2007 Aug 10;25(32):5968-77. Epub 2007 Jun 11. PubMed PMID: 17629365.
- 120: **Buonaguro L**, Tagliamonte M, Tornesello ML, Buonaguro FM. Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example. *Retrovirology*. 2007 May 21;4:34. Review. PubMed PMID: 17517125; PubMed Central PMCID: PMC1892567.
- 121: **Buonaguro L**, Tagliamonte M, Tornesello M, Buonaguro FM. Evolution of the HIV-1 V3 region in the Italian epidemic. *New Microbiol*. 2007 Jan;30(1):1-11. PubMed PMID: 17319594.
- 122: Tornesello ML, Duraturo ML, **Buonaguro L**, Vallefuoco G, Piccoli R, Palmieri S, Buonaguro FM. Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy. *Infect Agent Cancer*. 2007 Jan 3;2:1. PubMed PMID: 17201927; PubMed Central PMCID: PMC1779264.
- 123: Naderi HR, Tagliamonte M, Tornesello ML, Ciccozzi M, Rezza G, Farid R, Buonaguro FM, **Buonaguro L**. Molecular and phylogenetic analysis of HIV-1 variants circulating among injecting drug users in Mashhad-Iran. *Infect Agent Cancer*. 2006 Sep 19;1:4. PubMed PMID: 17150133; PubMed Central PMCID: PMC1635003.

- 124: Tagliamonte M, Vidal N, Tornesello ML, Peeters M, Buonaguro FM, **Buonaguro L**. Genetic and phylogenetic characterization of structural genes from non-B HIV-1 subtypes in Italy. *AIDS Res Hum Retroviruses*. 2006 Oct;22(10):1045-51. PubMed PMID: 17067276.
- 125: Tornesello ML, Duraturo ML, Botti G, Greggi S, Piccoli R, De Palo G, Montella M, **Buonaguro L**, Buonaguro FM; Italian HPV Working Group. Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population. *J Med Virol*. 2006 Dec;78(12):1663-72. PubMed PMID: 17063505.
- 126: **Buonaguro L**, Tornesello ML, Tagliamonte M, Gallo RC, Wang LX, Kamin-Lewis R, Abdelwahab S, Lewis GK, Buonaguro FM. Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. *J Virol*. 2006 Sep;80(18):9134-43. PubMed PMID: 16940524; PubMed Central PMCID: PMC1563937.
- 127: Tornesello ML, Duraturo ML, Waddell KM, Biryahwaho B, Downing R, Balinandi S, Lucas SB, **Buonaguro L**, Buonaguro FM. Evaluating the role of human papillomaviruses in conjunctival neoplasia. *Br J Cancer*. 2006 Feb 13;94(3):446-9. PubMed PMID: 16404433; PubMed Central PMCID: PMC2361142.
- 128: Aricò E, Wang E, Tornesello ML, Tagliamonte M, Lewis GK, Marincola FM, Buonaguro FM, **Buonaguro L**. Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. *J Transl Med*. 2005 Dec 29;3:45. PubMed PMID: 16384534; PubMed Central PMCID: PMC1360684.
- 129: Tornesello ML, Waddell KM, Duraturo ML, Biryahwaho B, Downing R, Lucas SB, Giani U, **Buonaguro L**, Buonaguro FM. TP53 codon 72 polymorphism and risk of conjunctival squamous cell carcinoma in Uganda. *Cancer Detect Prev*. 2005;29(6):501-8. Epub 2005 Nov 9. PubMed PMID: 16289503.
- 130: **Buonaguro L**, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. *J Virol*. 2005 Jun;79(11):7059-67. PubMed PMID: 15890945; PubMed Central PMCID: PMC1112107.
- 131: **Buonaguro L**, Tagliamonte M, Tornesello ML, Buonaguro FM. Evaluation of a modified version of Heteroduplex Mobility Assay for rapid screening of HIV-1 isolates in epidemics characterized by mono/dual clade predominance. *J Virol Methods*. 2005 Mar;124(1-2):123-34. Epub 2005 Jan 8. PubMed PMID: 15664060.
- 132: **Buonaguro L**, Tagliamonte M, Tornesello ML, Pilotti E, Casoli C, Lazzarin A, Tambussi G, Ciccozzi M, Rezza G, Buonaguro FM; Italian Concerted Action on PHI Treatment. Screening of HIV-1 isolates by reverse heteroduplex mobility assay and identification of non-B subtypes in Italy. *J Acquir Immune Defic Syndr*. 2004 Oct 1;37(2):1295-306. PubMed PMID: 15385738.
- 133: Tornesello ML, Duraturo ML, Salatiello I, **Buonaguro L**, Losito S, Botti G, Stellato G, Greggi S, Piccoli R, Pilotti S, Stefanon B, De Palo G, Franceschi S, Buonaguro FM. Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. *J Med Virol*. 2004 Sep;74(1):117-26. PubMed PMID: 15258977.
- 134: Buonaguro FM, Tornesello ML, **Buonaguro L**, Satriano RA, Ruocco E, Castello G, Ruocco V. Kaposi's sarcoma: aetiopathogenesis, histology and clinical features. *J Eur Acad Dermatol Venereol*. 2003 Mar;17(2):138-54. Review. PubMed PMID: 12705742.
- 135: **Buonaguro L**, Racioppi L, Tornesello ML, Arra C, Visciano ML, Biryahwaho B, Sempala SD, Giraldo G, Buonaguro FM. Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. *Antiviral Res*. 2002 Jun;54(3):189-201. PubMed PMID: 12062391.
- 136: **Buonaguro L**, Tagliamonte M, Tornesello ML, Ciuffreda D, Capiluppi B, Lopalco L, Lazzarin A, Tambussi G, Buonaguro FM. Molecular and phylogenetic characterization of HIV variants in Italian primary HIV infections (PHI): identification of non-B subtype variants. *J Biol Regul Homeost Agents*. 2002 Jan-Mar;16(1):44-8. PubMed PMID: 12003173.
- 137: **Buonaguro L**, Buonaguro FM, Tornesello ML, Mantas D, Beth-Giraldo E, Wagner R, Michelson S, Prevost MC, Wolf H, Giraldo G. High efficient production of Pr55(gag) virus-like particles expressing

- multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. *Antiviral Res.* 2001 Jan;49(1):35-47. PubMed PMID: 11166859.
- 138: Buonaguro FM, Tornesello ML, Salatiello I, Okong P, **Buonaguro L**, Beth-Giraldo E, Biryahwaho B, Sempala SD, Giraldo G. The Uganda study on HPV variants and genital cancers. *J Clin Virol.* 2000 Oct;19(1-2):31-41. PubMed PMID: 11091146.
- 139: Tornesello ML, Buonaguro FM, **Buonaguro L**, Salatiello I, Beth-Giraldo E, Giraldo G. Identification and functional analysis of sequence rearrangements in the long control region of human papillomavirus type 16 Af-1 variants isolated from Ugandan penile carcinomas. *J Gen Virol.* 2000 Dec;81(Pt 12):2969-82. PubMed PMID: 11086128.
- 140: **Buonaguro L**, Buonaguro FM, Russo F, Tornesello ML, Beth-Giraldo E, Wagner R, Wolf H, Giraldo G. A novel glycoprotein 120 sequence from an HIV type 1 isolate of the A clade identified in North Uganda. *AIDS Res Hum Retroviruses.* 1998 Sep 20;14(14):1287-9. PubMed PMID: 9764913.
- 141: Chang HC, Samaniego F, Nair BC, **Buonaguro L**, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. *AIDS.* 1997 Oct;11(12):1421-31. PubMed PMID: 9342064.
- 142: Tornesello ML, Buonaguro FM, Meglio A, **Buonaguro L**, Beth-Giraldo E, Giraldo G. Sequence variations and viral genomic state of human papillomavirus type 16 in penile carcinomas from Ugandan patients. *J Gen Virol.* 1997 Sep;78 (Pt 9):2199-208. PubMed PMID: 9292007.
- 143: Buonaguro FM, **Buonaguro L**, Del Gaudio E, Tornesello ML, Monaco M, Greco D, Corti P, Corti LT, Beth-Giraldo E, Giraldo G. V3 region genotyping of HIV isolates in northern Uganda: heteroduplex mobility assay, nucleotide sequence and phylogenetic analysis. *Italian-Ugandan Cooperation AIDS Program. Antibiot Chemother (1971).* 1996;48:39-48. PubMed PMID: 8726504.
- 144: **Buonaguro L**, Del Gaudio E, Monaco M, Greco D, Corti P, Beth-Giraldo E, Buonaguro FM, Giraldo G. Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. *The Italian-Ugandan Cooperation AIDS Program. J Virol.* 1995 Dec;69(12):7971-81. PubMed PMID: 7494310; PubMed Central PMCID: PMC189742.
- 145: **Buonaguro L**, Buonaguro FM, Giraldo G, Ensoli B. The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure. *J Virol.* 1994 Apr;68(4):2677-82. PubMed PMID: 8139045; PubMed Central PMCID: PMC236745.
- 146: **Buonaguro L**, Greco D, Tornesello ML, Rago M, Zaccarelli M, Curcio F, Castello G, Sguazzo N, Pipolo G, Beth-Giraldo E, et al. Analysis of HIV-1 env gene V3 loop sequence in a southern Italian cohort of intravenous drug users. *AIDS.* 1994 Feb;8(2):268-9. PubMed PMID: 8043234.
- 147: **Buonaguro L**, Buonaguro FM, Tornesello ML, Beth-Giraldo E, Del Gaudio E, Ensoli B, Giraldo G. Role of HIV-1 Tat in the pathogenesis of AIDS-associated Kaposi's sarcoma. *Antibiot Chemother (1971).* 1994;46:62-72. Review. PubMed PMID: 7826041.
- 148: Buonaguro FM, Tornesello ML, **Buonaguro L**, Del Gaudio E, Beth-Giraldo E, Giraldo G. Role of HIV as cofactor in HPV oncogenesis: in vitro evidences of virus interactions. *Antibiot Chemother (1971).* 1994;46:102-9. PubMed PMID: 7826030.
- 149: Ensoli B, **Buonaguro L**, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. *J Virol.* 1993 Jan;67(1):277-87. PubMed PMID: 8416373; PubMed Central PMCID: PMC237361.
- 150: Barillari G, **Buonaguro L**, Fiorelli V, Hoffman J, Michaels F, Gallo RC, Ensoli B. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression. Implications for AIDS-Kaposi's sarcoma pathogenesis. *J Immunol.* 1992 Dec 1;149(11):3727-34. PubMed PMID: 1431144.
- 151: **Buonaguro L**, Barillari G, Chang HK, Bohan CA, Kao V, Morgan R, Gallo RC, Ensoli B. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. *J Virol.* 1992 Dec;66(12):7159-67. PubMed PMID: 1279199; PubMed Central PMCID: PMC240407.

- 152: Bohan CA, Kashanchi F, Ensoli B, **Buonaguro L**, Boris-Lawrie KA, Brady JN. Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro. *Gene Expr.* 1992;2(4):391-407. PubMed PMID: 1282057; PubMed Central PMCID: PMC6057369.
- 153: Ensoli B, Barillari G, **Buonaguro L**, Gallo RC. Molecular mechanisms in the pathogenesis of AIDS-associated Kaposi's sarcoma. *Adv Exp Med Biol.* 1991;303:27-38. PubMed PMID: 1805571.
- 154: Bevilacqua MA, Costanzo F, **Buonaguro L**, Cimino F. Ferritin H and L mRNAs in human neoplastic tissues. *Ital J Biochem.* 1988 Jan-Feb;37(1):1-7. PubMed PMID: 3384636.